ArticleMolecular nutrition & food research2026
The Ganoderma atrum Polysaccharide PSG-1 Attenuates Acrylamide-Induced Hepatotoxicity by Modulating the FXR-FGF15-Mediated Gut-Liver Axis.
Article in Molecular nutrition & food research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Acrylamide (AA), a widespread food-processing contaminant, induces intestinal injury and hepatotoxicity by disrupting barrier function, redox balance, bile acid metabolism, and gut microbial ecology. This study examined the protective benefits of Ganoderma atrum polysaccharide (PSG-1), focusing on the gut-liver axis. PSG-1 reduced serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), and total bile acid (TBA) levels and improved liver histology. It also restored antioxidant defense by enhancing superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px) activities while lowering malondialdehyde (MDA). At the intestinal level, PSG-1 alleviated barrier disruption and reversed gut dysbiosis, restoring Lactobacillus abundance. This microbial modulation coincided with reactivation of the farnesoid X receptor (FXR)/fibroblast growth factor 15 (FGF15) pathway, which normalized hepatic cholesterol 7α-hydroxylase (CYP7A1) expression and improved bile acid homeostasis. PSG-1 also corrected retinol metabolism disorders by reducing lecithin-retinol acyltransferase (LRAT) and restoring retinol-binding protein 4 (RBP4). These results demonstrate that PSG-1 protects against AA-induced intestinal and hepatic injury through coordinated regulation of oxidative stress, gut microbiota composition, and FXR-mediated bile acid signaling along the gut-liver axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.